Jeffrey Matous, MD

Patient-Reported Outcomes from Patients with Waldenström Macroglobulinemia Treated with Ibrutinib-Rituximab: Results from iNNOVATE Study

Purpose of the Study: For patients with Waldenström macroglobuli- nemia (WM), anemia and fatigue can impair quality of life. Ibrutinib is the only once-daily inhibitor of Brutons tyrosine...

Bernhard Hauns ;

Christian Buske ;

Steve Treon , MD, PhD, FRCP, FACP;

Veronique Leblond ;

Alessandra Tedeschi ;

Judith Trotman ;

Ramón García-Sanz ;

David Macdonald ;

Meletios-Athanasios Dimopoulos ;

Beatrice Mahe ;

Charles Herbaux ;

Leonard Heffner ;

Marzia Varettoni ;

M. Lia Palomba ;

Constantine S. Tam ;

Chaim Shustik ;

Jeffrey Matous , MD;

Efstathios Kastritis ;

Jianling Li ;

Erik G. Poulsen ;

10/23/2019

Patient-Reported Outcomes from Patients with Waldenström Macroglobulinemia Treated with Ibrutinib-Rituximab: Results from iNNOVATE Study

Purpose of the Study: For patients with Waldenström macroglobuli- nemia (WM), anemia and fatigue can impair quality of life. Ibrutinib is the only once-daily inhibitor of Brutons tyrosine...

Erik G. Poulsen ;

Bernhard Hauns ;

Christian Buske ;

Steve Treon , MD, PhD, FRCP, FACP;

Veronique Leblond ;

Alessandra Tedeschi ;

Judith Trotman ;

Ramón García-Sanz ;

David Macdonald ;

Meletios-Athanasios Dimopoulos ;

Beatrice Mahe ;

Charles Herbaux ;

Leonard Heffner ;

Marzia Varettoni ;

M. Lia Palomba ;

Constantine S. Tam ;

Chaim Shustik ;

Jeffrey Matous , MD;

Efstathios Kastritis ;

Jianling Li ;

10/23/2019

Jeffrey Matous, MD, Sarah Cannon Research Institute

Conference Coverage

Talquetamab Plus Pomalidomide Shows Promising Efficacy, Manageable Safety for Patients With MM

01/11/2024

Jeffrey Matous , MD;

At the 65th ASH Annual Meeting, Jeffrey Matous, MD, shared initial trial results that talquetamab plus pomalidomide demonstrated rapid, deep responses among patients with R/R multiple myeloma and ≥2 prior lines of therapy.

At the 65th ASH Annual Meeting,...

01/11/2024

Oncology